Abstract
Early CoVID-19 growth obeys: 
, with Ko = [(ln 2)/(tdbl)], where tdbl is the pandemic growth doubling time. Given 
, the daily number of new CoVID-19 cases is 
. Implementing society-wide Social Distancing increases the tdbl doubling time, and a linear function of time for tdbl was used in our Initial Model:
to describe these changes, where the [t]-axis is time-shifted from the 
–axis back to the pandemic start, and Go ≡ [KA/ γo]. While this No[t] successfully modeled the USA CoVID-19 progress from 3/2020 to 6/2020, this equation could not easily model some quickly decreasing ρ[t] cases (“fast pandemic shutoff “), indicating that a second process was involved. This situation was most evident in the initial CoVID-19 data from China, South Korea, and Italy. Modifying Zo[t] to allow exponential cutoffs:
resulted in an Enhanced Initial Model (EIM) that significantly improved data fits for these cases.
After 6/2020, many regions of the USA “opened up”, loosening their Social Distancing requirements, which led to a sudden USA CoVID-19 Resurgence. Extrapolating the USA No[t] 3/2020-6/2020 results to 9/2020 as an Initial Model Baseline (IMB), and subtracting this IMB from the newer USA data gives a Resurgence Only function, which is analyzed here. This USA CoVID-19 Resurgence function differs significantly from the No[t] IMB functional form, but it was well-modeled by the NA[t] fast pandemic shutoff function. These results indicate that: (a) the gradual increase in tdbl doubling time from society-wide shut-downs is likely due to eliminating of a large number of population gathering points that could have enabled CoVID-19 spread; and (b) having a non-zero δ o fast pandemic shutoff is likely due to more people wearing masks more often [with 12 Figures].
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No External Funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No Human Subjects involved, as this is a Data Analysis Project. No IRB approvals needed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used is in the Public Domain or was on the CoVID-19 website maintained by bing.com.
